A single‐center review of pre‐exposure prophylaxis with tixagevimab–cilgavimab in solid organ transplant recipients
Transplant Infectious Disease · 2023
DOI: 10.1111/tid.14086 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant Infectious Disease, 2023. Verfasst von Faiza Morado und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Keck Hospital of USC, University of Southern California, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Pre-Exposure Prophylaxis, COVID-19, Organ Transplantation. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Coronavirus disease 2019 (COVID‐19) continues to negatively impact solid organ transplant recipients (SOTr). Data on the use of tixagevimab–cilgavimab (tix‐cil) in vaccinated SOTr during circulation of Omicron and its subvariants are limited. Therefore, this single‐center review was conducted to evaluate tix‐cil efficacy in multiple organ transplant groups during a study period where Omicron B.1.1.529, BA.2.12.1, and BA.5 predominated.
Methods
In this single‐center retrospective study, we evaluated the incidence of COVID‐19 infection in adult SOTr who did or did not receive pre‐exposure prophylaxis (PrEP) with tix‐cil. SOTr were included if they were at least 18 years of age and met emergency use authorization criteria for tix‐cil use. The primary outcome analyzed was the incidence of COVID‐19 infection.
Results
Ninety SOTr met inclusion criteria and comprised of two groups, tix‐cil PrEP ( n = 45) and no tix‐cil PrEP ( n = 45). Of SOTr who received tix‐cil PrEP, three (6.7%) developed COVID‐19 infection, compared to eight (17.8%) in the no tix‐cil PrEP group ( p = .20). Of the 11 SOTr diagnosed with COVID‐19, 15 (82.2%) were fully vaccinated against COVID‐19 prior to transplantation. Moreover, 18.2% and 81.8% of the COVID‐19 cases observed were asymptomatic and mild‐to‐moderate, respectively.
Discussion
Our study results, which included months when BA.5 was in increased circulation, suggest no significant difference in COVID‐19 infection with or without use of tix‐cil PrEP in our solid organ transplant groups. As the COVID‐19 pandemic continues to evolve, clinical utility of tix‐cil should be evaluated against new, emerging strains. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, Keck Hospital of USC, University of Southern California, Los Angeles, California, USA.
- USC Transplant Institute, Keck Hospital of USC, University of Southern California, Los Angeles, California, USA.
- Division of Infectious Disease, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
ORCID-Profile: Faiza Morado, Roland Davoudi, Pnada Kawewat-Ho, Rachel Cartus, Suhail A Shaikh
Zitieren
APA
Morado, F., Davoudi, R., Kawewat-Ho, P., Nanda, N., Cartus, R., & Shaikh, S. A. (2023). A single‐center review of pre‐exposure prophylaxis with tixagevimab–cilgavimab in solid organ transplant recipients. Transplant Infectious Disease. https://doi.org/10.1111/tid.14086
Vancouver
Morado F, Davoudi R, Kawewat-Ho P, Nanda N, Cartus R, Shaikh SA. A single‐center review of pre‐exposure prophylaxis with tixagevimab–cilgavimab in solid organ transplant recipients. Transplant Infectious Disease. 2023. doi:10.1111/tid.14086
BibTeX
@article{Morado2023,
author = {Morado, Faiza and Davoudi, Roland and Kawewat-Ho, Pnada and Nanda, Neha and Cartus, Rachel and Shaikh, Suhail A},
title = {A single‐center review of pre‐exposure prophylaxis with tixagevimab–cilgavimab in solid organ transplant recipients},
journal = {Transplant Infectious Disease},
year = {2023},
doi = {10.1111/tid.14086}
}
EUVIMED